Navigation Links
Patient Temperature Management Systems Enjoying Wider Usage
Date:11/19/2008

LONDON, Nov. 19 /PRNewswire/ -- With issues around patient comfort gaining momentum, hospitals and healthcare decision makers are recognising the need to consider patients' relief and welfare. This is leading to a growing demand for patient temperature management systems, which are being used for a greater number of patients and not just the aged and weak.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (http://www.medicaldevices.frost.com), European Patient Temperature Management Systems, finds that the market earned revenues of $366.0 million in 2007 and estimates this to reach $999.0 million in 2014.

"Heightened awareness about the numerous benefits of patient temperature management systems in surgical settings is aiding their increased uptake," notes Frost & Sullivan Industry Analyst Radha Sawhny. "The increasing proof of the long-term health benefits and reduced risks of contracting disease and infection in an operating environment they offer are the strong reasons for the demand."

Some patient temperature management systems are more established, their merits better known and, hence, their adoption rates higher than others. However, one of the biggest challenges in the European patient temperature management systems market relates to the lack of information about the varied merits of the systems on offer.

The market has two categories of products. The first are those aimed at therapeutic hypothermia and the reduction of fever with the use of surface and invasive warming and cooling devices. The second category includes those that maintain normothermia (normal body temperature) in patients exposed to the surgical environment and due for a surgical procedure. These therapies i
'/>"/>

SOURCE Frost & Sullivan
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Cancer survival rates impact type of Web communities used by patients
2. Indigo Ointment Benefits Psoriasis Patients
3. A postcode lottery still exists for cancer patients with exceptional circumstances
4. U of U researchers to use patients own stem cells to treat heart failure
5. Predicting the future for patients with severe traumatic brain injury
6. CAPHOSOL results in minimal oral mucositis and pain in head/neck cancer patients
7. Canadian cold/flu breakthrough remedy undergoes NCI-sponsored trial in leukemia patients
8. Intervention program boosts survival in breast cancer patients
9. Lung Cancer Genetics Different in Black Patients: Study
10. High Blood-Pressure Patients Can See Improvement Through Guided Breathing
11. Lung Cancer Patients Get Blamed for Their Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3Mirixa Corporation Announces Key New Hires 12958 1Mirixa Corporation Announces Key New Hires 12958 2Landmark project to map genomics of complex ant systems 9188 1Landmark project to map genomics of complex ant systems 9188 2European Health Care Institutions Forced to Select Lower Priced Interventional Cardiology Devices 51202 1European Health Care Institutions Forced to Select Lower Priced Interventional Cardiology Devices 51202 2